Strategic Outsourcing Debate
Lisa Henderson discusses the debate around aligning of sponsor and CRO in a more integrated way to run clinical trials from a project or portfolio standpoint and gain efficiencies and ultimately save money.
Lisa Henderson on the debate surrounding strategic outsourcing, which is the aligning of sponsor and CRO in a more integrated way to run clinical trials from a project or portfolio standpoint and gain efficiencies and ultimately save money.
Additional links:
- April 2013 article, Challenging the Value of Strategic Partnerships in Clinical Trial Outsourcing.
- PAREXEL's Strategic Partnerships 2013.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
